Evaluating Novel Nonhormonal Approaches for the Treatment of Menopausal Vasomotor Symptoms

This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP Nexus 2022.

Program Description

Menopause, the cessation of menstrual cycles, occurs for every woman, typically during their late 40s or early 50s. This transition may have varying presentation of bothersome symptoms that affect quality of life, sleep pattern, and daily routine, which warrants an individualized approach to care. Among these challenges, 60% to 85% of women struggle most with vasomotor symptoms (VMS), with 30% experiencing severe VMS that can last from 7 to 10 years. Menopausal hormone therapy is the standard of care for treating VMS, but adverse effects and numerous contraindications can limit its use in patients. There are several emerging nonhormonal options on the horizon, including fezolinetant and osanetant, selective neurokinin-3 receptor antagonists, and elinzanetant, a dual neurokinin-1,3 receptor antagonist. Managed care pharmacists are well positioned to assess VMS, recommend appropriate and personalized treatment plans, and provide education on therapies to optimize their care. This program will explore resources and challenges managed care professionals should be aware of regarding VMS treatment as well as the significance of individualized care associated with menopause.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: October 21, 2022
Expiration date: October 21, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the health burden associated with vasomotor symptoms (VMS) in menopause and the risk/benefit profile for hormonal therapy.
• Analyze the efficacy and safety data for investigational nonhormonal neurokinin-3 receptor antagonists and the dual neurokinin-1,3 receptor antagonist in the treatment and management of VMS.
• Investigate the healthcare resource utilization and economic burdens associated with VMS and the need for a personalized approach in treatment selection.